Printer Friendly

Consider this probiotic for functional abdominal pain.

In the article, "When can infants and children benefit from probiotics?" (J Fam Pract. 2016;65:789-794), Dassow et al recommended probiotics as a therapeutic tool for reducing abdominal pain associated with pediatric irritable bowel syndrome (IBS). There are several types of functional disorders in childhood with related abdominal pain, the most common of which are IBS and functional abdominal pain (FAP). (1,2)

Several recent randomized placebo-controlled trials--one of which I led--have shown that Lactobacillus reuteri DSM 17938 is a beneficial treatment for FAP in children. (3-5) When compared with placebo, this probiotic agent significantly reduced the frequency and intensity of FAP in children.

Family physicians should consider this probiotic microorganism as a potential therapeutic tool for IBS, as well as childhood FAP.

Zvi Weizman, MD

Beer-Sheva, Israel

References

(1.) Childhood functional GI disorders: child/adolescent. In: Drossman DA CE, Delvaux M, Spiller RC, et al, eds. Rome III: the Junctional gastrointestinal disorders. 3rd ed. McLean, VA: Degnon Associates, Inc; 2006:895-897.

(2.) Brown LK, Beattie RM, Tighe MR Practical management of functional abdominal pain in children. Arch Dis Child. 2016:101:677-683.

(3.) Romano C, Ferrau' V, Cavataio F, et al. Lactobacillus reuteri in children with functional abdominal pain (FAP). J Paediatr Child Health. 2014;50:E68-E71.

(4.) Weizman Z, Abu-Abed J, Binsztok M. Lactobacillus reuteri DSM 17938 for the management of functional abdominal pain in childhood: A randomized, double-blind, placebo-controlled trial. J Pediatr. 2016;174:160-164.el.

(5.) Jadresin O, Hojsak I, Misak Z, et al. Lactobacillus reuteri DSM 17938 in the treatment of functional abdominal pain in children RCT study. J Pediatr Gastroenterol Nutr. 2017;64:925-929.

COPYRIGHT 2017 Quadrant Healthcom, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:LETTERS
Author:Weizman, Zvi
Publication:Journal of Family Practice
Article Type:Letter to the editor
Geographic Code:1USA
Date:Jul 1, 2017
Words:271
Previous Article:Rewriting the script on polypharmacy.
Next Article:Gradual vs abrupt smoking cessation: each has its place.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters